{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:13:57Z","timestamp":1753892037104,"version":"3.41.2"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Chloroquine was once thought to be a promising treatment for COVID-19 but it quickly failed due to its inefficiency and association with increased mortality. Further, comorbidities such as hypertension may have contributed this failure. The safety and toxicity of chloroquine at doses required for treating SARS-CoV-2 infection in hypertensive patients remain unknown. Herein, to investigate these effects, we performed a safety evaluation of chloroquine at the approved dose (63\u00a0mg\/kg) and at a high dose (126\u00a0mg\/kg) in hypertensive rats. We found that chloroquine increased the mortality of hypertensive rats to 18.2% and 100%, respectively, after 7\u00a0days. During the chloroquine exposure period, the bodyweight, feed, and water consumption of hypertensive rats were decreased significantly. In addition, we show that chloroquine induces prolongation of QTc interval, elevation of LDH and CK, and histopathological damage of the myocardium in hypertensive rats. Ocular toxicity was observed in hypertensive rats in the form of hemorrhage in the eyes and retinal damage. Furthermore, we also observed intestinal toxicity in hypertensive rats, which presented as thinning intestinal walls with hemorrhagic contents, and histopathological changes of the jejunum. Hepatotoxicity was also evidenced by elevated ALT, and vacuolization of hepatocytes was also observed. Nephrotoxicity was observed only in high dose chloroquine-treated hypertensive rats, presenting as alterations of urinalysis and renal function. Immune alterations were also found in high-dose chloroquine-treated hypertensive rats with elevation of serum IL-10, IL-1\u03b2 and GRO, and moderate damage to the spleen. In summary, this study partially explains the reason for the failure of chloroquine as a COVID-19 therapy, and underlines the importance of safety evaluation and medical supervision of chloroquine to avoid patient harm, especially to those with hypertension.<\/jats:p>","DOI":"10.3389\/fphar.2022.1051694","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T06:20:33Z","timestamp":1669789233000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Hypertension related toxicity of chloroquine explains its failure against COVID-19: Based on rat model"],"prefix":"10.3389","volume":"13","author":[{"given":"Junqi","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizhong","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuling","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenda","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanxiang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuge","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/0974-8490.99071","article-title":"Sub-acute effect of N(G)-nitro-l-arginine methyl-ester (L-NAME) on biochemical indices in rats: Protective effects of Kolaviron and extract of Curcuma longa L","volume":"4","author":"Adaramoye","year":"2012","journal-title":"Pharmacogn. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1038\/s41467-021-22446-z","article-title":"Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials","volume":"12","author":"Axfors","year":"2021","journal-title":"Nat. Commun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/978-1-60327-389-3_27","article-title":"Rat models of cardiovascular diseases","volume":"597","author":"Bader","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/jat.864","article-title":"Chloroquine poisoning in Zimbabwe: A toxicoepidemiological study","volume":"22","author":"Ball","year":"2002","journal-title":"J. Appl. Toxicol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"B8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa2016638","article-title":"A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19","volume":"383","author":"Boulware","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.kint.2020.03.005","article-title":"Kidney disease is associated with in-hospital death of patients with COVID-19","volume":"97","author":"Cheng","year":"2020","journal-title":"Kidney Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1097\/00003246-199607000-00021","article-title":"Treatment of acute chloroquine poisoning: A 5-year experience","volume":"24","author":"Clemessy","year":"1996","journal-title":"Crit. Care Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for covid-19 - interim WHO solidarity trial results","volume":"384","author":"Consortium","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.apsb.2020.04.007","article-title":"Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model","volume":"10","author":"Cui","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"B15","doi-asserted-by":"publisher","first-page":"100085","DOI":"10.1016\/j.medidd.2021.100085","article-title":"The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review","volume":"10","author":"Das","year":"2021","journal-title":"Med. Drug Discov."},{"key":"B16","first-page":"11","article-title":"Hydroxychloroquine for sars CoV2 prophylaxis in healthcare workers - a multicentric cohort study assessing effectiveness and safety","volume":"69","author":"Dinesh","year":"2021","journal-title":"J. Assoc. Physicians India"},{"unstructured":"COVID-19: Chloroquine and hydroxychloroquine only to Be used in clinical trials or emergency use programs2020","key":"B3"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.4269\/ajtmh.20-0276","article-title":"Case report: Hepatotoxicity associated with the use of hydroxychloroquine in a patient with COVID-19","volume":"102","author":"Falcao","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ijid.2021.04.009","article-title":"A call to caution when hydroxychloroquine is given to elderly patients with COVID-19","volume":"106","author":"Gabor","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"109954","DOI":"10.1016\/j.cbi.2022.109954","article-title":"Safety considerations of chloroquine in the treatment of patients with diabetes and COVID-19","volume":"361","author":"Gao","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jamainternmed.2020.3539","article-title":"Risk factors associated with mortality among patients with COVID-19 in intensive care units in lombardy, Italy","volume":"180","author":"Grasselli","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"115412","DOI":"10.1016\/j.taap.2021.115412","article-title":"Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress","volume":"414","author":"Gregorio","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41586-020-2575-3","article-title":"Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2","volume":"585","author":"Hoffmann","year":"2020","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1093\/nsr\/nwaa113","article-title":"Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19","volume":"7","author":"Huang","year":"2020","journal-title":"Natl. Sci. Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"m2980","DOI":"10.1136\/bmj.m2980","article-title":"Drug treatments for Covid-19: Living systematic review and network meta-analysis","volume":"12","author":"Izcovich","year":"2022","journal-title":"BMJ Open"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1111\/bcp.14598","article-title":"Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic","volume":"87","author":"Junqueira","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"106314","DOI":"10.1016\/j.ijantimicag.2021.106314","article-title":"Timing and dosage may be the key in the realisation of hydroxychloroquine\u00a0+\u00a0azithromycin treatment benefit in Covid-19 elderly patients","volume":"57","author":"Lacout","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1161\/hyp.0000000000000090","article-title":"Animal models of hypertension: A scientific statement from the American heart association","volume":"73","author":"Lerman","year":"2019","journal-title":"Hypertension"},{"key":"B28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.34172\/apb.2021.022","article-title":"Nephrotoxicity of chloroquine and hydroxychloroquine in COVID-19 patients","volume":"11","author":"Mahmoudi","year":"2021","journal-title":"Adv. Pharm. Bull."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/15563650.2020.1748194","article-title":"Chloroquine and hydroxychloroquine to treat COVID-19: Between hope and caution","volume":"59","author":"Megarbane","year":"2021","journal-title":"Clin. Toxicol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1001\/jamacardio.2020.1834","article-title":"Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)","volume":"5","author":"Mercuro","year":"2020","journal-title":"JAMA Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"E019","DOI":"10.3760\/cma.j.issn.1001-0939.2020.0019","article-title":"Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia","volume":"43","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"B34","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/pubmed\/fdaa074","article-title":"HyPE study: Hydroxychloroquine prophylaxis-related adverse events' analysis among healthcare workers during COVID-19 pandemic: A rising public health concern","volume":"42","author":"Nagaraja","year":"2020","journal-title":"J. Public Health"},{"unstructured":"Diagnosis and treatment of COVID-19 in China (the six edition for trial)2020","key":"B10"},{"unstructured":"Diagnosis and treatment Program of COVID-19 in China(the ninth edition for trial)2021","key":"B11"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e12476","DOI":"10.15252\/emmm.202012476","article-title":"Hydroxychloroquine in rheumatic autoimmune disorders and beyond","volume":"12","author":"Nirk","year":"2020","journal-title":"EMBO Mol. Med."},{"volume-title":"Guidelines for the treatment of malaria","year":"2015","author":"Organization","key":"B36"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e648","DOI":"10.1097\/FJC.0000000000001116","article-title":"Role of hypertension on the severity of COVID-19: A review","volume":"78","author":"Peng","year":"2021","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"878","DOI":"10.7326\/M20-7918","article-title":"Reported adverse drug reactions associated with the use of hydroxychloroquine and chloroquine during the COVID-19 pandemic","volume":"174","author":"Perez","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","article-title":"Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases","volume":"23","author":"Rainsford","year":"2015","journal-title":"Inflammopharmacology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"9023","DOI":"10.1038\/s41598-021-88509-9","article-title":"An open-label randomized controlled trial evaluating the efficacy of chloroquine\/hydroxychloroquine in severe COVID-19 patients","volume":"11","author":"Rea-Neto","year":"2021","journal-title":"Sci. Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/j.1476-5381.1990.tb14151.x","article-title":"Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo","volume":"101","author":"Rees","year":"1990","journal-title":"Br. J. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1093\/jn\/123.11.1939","article-title":"Ain-93 purified diets for laboratory rodents - final report of the American institute of nutrition ad hoc writing committee on the reformulation of the ain-76a rodent diet","volume":"123","author":"Reeves","year":"1993","journal-title":"J. Nutr."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM198801073180101","article-title":"Treatment of severe chloroquine poisoning","volume":"318","author":"Riou","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1001\/jama.2020.8630","article-title":"Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state","volume":"323","author":"Rosenberg","year":"2020","journal-title":"JAMA"},{"key":"B45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12974-021-02323-8","article-title":"Brain injury, endothelial injury and inflammatory markers are elevated and express sex-specific alterations after COVID-19","volume":"18","author":"Savarraj","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1001\/jama.2020.22240","article-title":"Effect of hydroxychloroquine on clinical status at 14 Days in hospitalized patients with COVID-19: A randomized clinical trial","volume":"324","author":"Self","year":"2020","journal-title":"JAMA"},{"key":"B47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/jcpt.13267","article-title":"Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing","volume":"46","author":"Shah","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"623","DOI":"10.7326\/M20-4207","article-title":"Hydroxychloroquine in nonhospitalized adults with early COVID-19 : A randomized trial","volume":"173","author":"Skipper","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0163-7258(93)90056-j","article-title":"Chloroquine: Mechanism of drug action and resistance in Plasmodium falciparum","volume":"57","author":"Slater","year":"1993","journal-title":"Pharmacol. Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"m1849","DOI":"10.1136\/bmj.m1849","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial","volume":"369","author":"Tang","year":"2020","journal-title":"Bmj-British Med. J."},{"key":"B51","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.mayocpiqo.2020.10.005","article-title":"Cardiac toxicity of chloroquine or hydroxychloroquine in patients with COVID-19: A systematic review and meta-regression analysis","volume":"5","author":"Tleyjeh","year":"2021","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"unstructured":"Request for emergency use authorization for use of chloroquine phosphate or hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of 2019 coronavirus disease2020","key":"B2"},{"key":"B52","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ijid.2020.12.010","article-title":"More gastro-intestinal adverse events in non-ICU hospitalised COVID-19 patients treated with chloroquine versus hydroxychloroquine","volume":"103","author":"Verheijen","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000503882","article-title":"The chronic adverse effect of chloroquine on kidney in rats through an autophagy dependent and independent pathways","volume":"144","author":"Wang","year":"2020","journal-title":"Nephron"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e1003252","DOI":"10.1371\/journal.pmed.1003252","article-title":"COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology","volume":"17","author":"White","year":"2020","journal-title":"PLoS Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","article-title":"Pathophysiology, transmission, Diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review","volume":"324","author":"Wiersinga","year":"2020","journal-title":"JAMA"},{"key":"B56","doi-asserted-by":"publisher","first-page":"4155","DOI":"10.1111\/bph.13990","article-title":"Chloroquine is a potent pulmonary vasodilator that attenuates hypoxia-induced pulmonary hypertension","volume":"174","author":"Wu","year":"2017","journal-title":"Br. J. Pharmacol."},{"volume-title":"Experimental methodology of Pharmacology","year":"2002","author":"Xu","key":"B57"},{"key":"B58","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","article-title":"COVID-19 and the cardiovascular system","volume":"17","author":"Zheng","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in wuhan, China: A retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1051694\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T06:20:45Z","timestamp":1669789245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1051694\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":59,"alternative-id":["10.3389\/fphar.2022.1051694"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1051694","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2022,11,30]]},"article-number":"1051694"}}